Publications

In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. by Kohlhoff SA, Huband MD and Hammerschlag MR published in Antimicrob. Agents Chemother. 2014; 58 (12): 7595-7596

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes. by Dallow J, Otterson LG, Huband MD, Krause KM and Nichols WW published in Int. J. Antimicrob. Agents. 2014; 44 (6): 552-556

Daptomycin activity when tested against 164,457 bacterial isolates from hospitalized patients: Summary of 8 years of a worldwide surveillance programme (2005-2012). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (5): 465-469

Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in J. Infect. 2014; 69 (3): 266-277

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-2012). by Sader HS, Farrell DJ, Castanheira M, Flamm RK and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (10): 2713-2722

Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. by Ross JE, Scangarella-Oman NE, Flamm RK and Jones RN published in J. Clin. Microbiol. 2014; 52 (7): 2629-2632

Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria. by Pfaller MA, Diekema DJ, Jones RN and Castanheira M published in J. Clin. Microbiol. 2014; 52 (9): 3223-3229

Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. by Pfaller MA, Castanheira M, Messer SA, Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 79 (2): 198-204

Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens. by Montgomery AB, Rhomberg PR, Abuan T, Walters KA and Flamm RK published in Antimicrob. Agents Chemother. 2014; 58 (7): 3714-3719

Amikacin/fosfomycin (5:2 ratio): characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics. by Montgomery AB, Rhomberg PR, Abuan T, Walters KA and Flamm RK published in Antimicrob. Agents Chemother. 2014; 58 (7): 3708-3713

Linezolid update: Stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. by Mendes RE, Deshpande LM and Jones RN published in Drug Resist. Updat. 2014; 17 (1-2): 1-12

Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. by Mendes RE, Costello AJ, Jacobs MR, Biek D, Critchley IA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 80 (1): 19-25

Decreased ceftriaxone susceptibility in emerging (35B, 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the USA (2011 – 2012): Ceftaroline remains active in vitro among beta-lactam agents. by Mendes RE, Biek D, Critchley IA, Farrell DJ, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (8): 4923-4927

Candidemia surveillance in Iowa: emergence of echinocandin resistance. by Matsumoto E, Boyken L, Tendolkar S, McDanel J, Castanheira M, Pfaller M and Diekema D published in Diagn. Microbiol. Infect. Dis. 2014; 79 (2): 205-208

Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin. by Lodise TP, Drusano GL, Lazariu V, El-Fawal N, Evans A, Graffunder E, Stellrecht K, Mendes RE, Jones RN, Cosler L and McNutt LA published in J. Antimicrob. Chemother. 2014; 69 (9): 2547-2555

Regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians! by Jones RN, Mendes RE and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2014; 80 (1): 91-92

In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection. by Fernandez-Silva F, Lackner M, Capilla J, Mayayo E, Sutton D, Castanheira M, Fothergill AW, Lass-Florl C and Guarro J published in Antimicrob. Agents Chemother. 2014; 58 (7): 3646-3649

Revised reference broth microdilution method for testing telavancin: Effect on MIC results and correlation with other testing methodologies. by Farrell DJ, Mendes RE, Rhomberg PR and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (9): 5547-5551

Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. by Castanheira M, Messer SA, Jones RN, Farrell DJ and Pfaller MA published in Int. J. Antimicrob. Agents. 2014; 44 (4): 320-326

Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying ß-lactamases prevalent in the United States. by Castanheira M, Williams G, Jones RN and Sader HS published in Microb. Drug Res. 2014; 20 (5): 436-440

Quality control MIC ranges for telavancin with application of a revised CLSI reference broth microdilution method. by Ross JE, Mendes RE and Jones RN published in J. Clin. Microbiol. 2014; 52 (9): 3399-3401

Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values by Pfaller MA, Castanheira M, Messer SA, Rhomberg PR, Dietrich RR and Jones RN published in Mycopathologia 2014; 178 (1-2): 1-9

In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011). by Flamm RK, Jones RN and Sader HS published in J. Global Antimicrob. Res. 2014; 2 (2): 183-189

Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: An epidemiological and structural perspective. by Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP and Lahiri SD published in J. Antimicrob. Chemother. 2014; 69 (8): 2065-2075

Ceftaroline activity tested against bacterial isolates from pediatric patients: Results from the Assessing Worldwide Antimicrobial Resistance and Evaluation program for the United States (2011-2012). by Sader HS, Mendes RE, Farrell DJ, Flamm RK and Jones RN published in Pediatr. Infect. Dis. J. 2014; 33 (8): 837-842

Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (7): 3882-3888

Oritavancin activity against Staphylococcus aureus causing invasive infections in USA and European hospitals. A five-year international surveillance program. by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (5): 2921-2924

Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). by Flamm RK, Sader HS and Jones RN published in Braz. J. Infect. Dis. 2014; 18 (2): 187-195

Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: Results from the AWARE Program, 2009-2011. by Flamm RK, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 437-442

Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal, and urinary tract infections in United States medical centers (2012). by Flamm RK, Farrell DJ, Sader HS and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (6): 1589-1598

Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012). by Flamm RK, Farrell DJ, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 449-456

Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012). by Farrell DJ, Sader HS, Flamm RK and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (6): 533-539

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to daptomycin, linezolid, vancomycin and strains with defined SCCmec types. by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (4): 323-327

Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. by Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Florl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J and Turnidge J published in Antimicrob. Agents Chemother. 2014; 58 (4): 2006-2012

Detection of NDM-1-producing Enterobacteriaceae in Romania: Report of the SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Flonta M, Jones RN and Castanheira M published in J. Med. Microbiol. 2014; 63 (Pt 3): 483-484

Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel. by Castanheira M, Jones RN and Sader HS published in J. Chemother. 2014; 26 (4): 202-210

Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-2011 in 14 European and Mediterranean countries. by Castanheira M, Deshpande LM, Costello A, Davies TA and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (7): 1804-1814

Frequency of occurrence and antimicrobial susceptibility of gram-negative bacteremia isolates in patients with urinary tract infection: Results from United States and European hospitals (2009-2011). by Sader HS, Flamm RK and Jones RN published in J. Chemother. 2014; 26 (3): 133-138

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized with pneumonia in United States and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (4): 328-334

Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. by Mendes RE, Sader HS, Flamm RK and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (6): 1579-1581

Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program: Report of linezolid activity over 9 years (2004 – 2012). by Mendes RE, Hogan PA, Streit JM, Jones RN and Flamm RK published in J. Antimicrob. Chemother. 2014; 69 (6): 1582-1588

Post ß-lactamase inhibitor effect of tazobactam in combination with ceftolozane and tested against ESBL-producing strains. by Sader HS, Rhomberg PR and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2434-2437

Ceftaroline activity tested against uncommonly isolated gram-positive pathogens: Report from the SENTRY Antimicrobial Surveillance Program (2008- 2011). by Sader HS, Jones RN, Stilwell MG and Flamm RK published in Int. J. Antimicrob. Agents. 2014; 43 (3): 284-286

Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2274-2280

Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida using CLSI methods and interpretive criteria. by Pfaller MA, Messer SA, Diekema DJ, Jones RN and Castanheira M published in J. Clin. Microbiol. 2014; 52 (1): 108-114

Update on Acinetobacter species: Mechanisms of antimicrobial resistances and contemporary in vitro activity of minocycline and other treatment options. by Castanheira M, Mendes RE and Jones RN published in Clin. Infect. Dis. 2014; 59 (Suppl 6): S367-373

Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. by VanScoy BD, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Jones RN, Friedrich LV, Steenbergen JN and Ambrose PG published in Antimicrob. Agents Chemother. 2014; 58 (10): 6024-6031

Resistance surveillance program report for selected European nations (2011). by Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 429-436

Retrospective molecular analysis of DIM-1 metallo-ß-lactamase discovered in Pseudomonas stutzeri from India in 2000. by Deshpande LM, Jones RN, Woosley LN and Castanheira M published in Antimicrob. Agents Chemother. 2014; 58 (1): 596-598

Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. by Castanheira M, Woosley LN, Messer SA, Diekema DJ, Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2014; 58 (1): 577-580